AbbVie Inc. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
AbbVie Inc. (ABBV) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $25.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-20
- AbbVie Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $25.00M, a 44.44% decline from fiscal 2024.
- AbbVie Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $45.00M, a 15.38% increase from fiscal 2023.
- AbbVie Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $39.00M, a 64.55% decline from fiscal 2022.
- AbbVie Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $110.00M, a 223.53% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month as first filed |
|---|---|---|
| 2025-12-31 | $25.00M 10-K · filed 2026-02-20 | |
| 2024-12-31 | $45.00M 10-K · filed 2026-02-20 | |
| 2023-12-31 | $39.00M 10-K · filed 2026-02-20 | |
| 2022-12-31 | $110.00M 10-K · filed 2025-02-14 | |
| 2021-12-31 | $34.00M 10-K · filed 2024-02-20 | |
| 2020-12-31 | $73.00M 10-K · filed 2023-02-17 | |
| 2019-12-31 | $33.00M 10-K · filed 2022-02-18 | |
| 2018-12-31 | $7.00M 10-K · filed 2021-02-19 | |
| 2017-12-31 | $16.00M 10-K · filed 2020-02-21 | |
| 2016-12-31 | $8.00M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $8.00M 10-K · filed 2018-02-16 | -$8.00M 10-K · filed 2016-02-19 |
| 2014-12-31 | $2.00M 10-K · filed 2017-02-17 | -$2.00M 10-K · filed 2015-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |